BACKGROUND: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) study compares cardiovascular outcomes in 15,314 eligible patients from 31 countries randomized to valsartan or amlodipine-based treatment. METHODS: The blood pressure (BP) trends are analyzed in 13,449 of VALUE study patients who had baseline BP and 24 months BP and treatment data. RESULTS: In a cohort of 12,570 patients, baseline 24 and 30 months BP, but not 30 months treatment data, were available. Of 13,449 patients, 92% (N = 12,398) received antihypertensive therapy at baseline. The baseline BP was 153.5/86.9 mm Hg in treated compared to 168.1.8/95.3 mm Hg in 1051 untreated patients. After 6 months both groups had indistinguishable BP values. At 12 months the B...
Purposes: The purpose of this study was threefold. First, to examine how both the effectiveness of v...
Study design: An open- label, multicentre study was conducted to evaluate the antihypertensive effic...
Purpose: Blood pressure variability is associated with traditional cardiovascular risk factors, but ...
term Use Evaluation (VALUE) study compares cardiovascu-lar outcomes in 15,314 eligible patients from...
Background: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) study compares cardiovas...
BACKGROUND: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to te...
Purpose: The VALUE Trial compares cardiovascular outcomes in 15,314 eligible patients from 31 countr...
Essential hypertension is a major Public Health issue. Although the number of treated hypertensive p...
BACKGROUND: In the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial the primary out...
(VALUE) trial was designed to test whether, for the same achieved blood pressures, regimens based on...
SummaryBackgroundHypertensive patients with established cardiovascular or renal disease (ECVRD) have...
Valsartan is an orally active, selective antagonist of the angiotensin II-1 (AT1) receptor developed...
SummaryBackgroundEuropean guidelines recommend that antihypertensive management should be graded as ...
OBJECTIVE: The ambulatory blood pressure (ABP) monitoring substudy of the Valsartan Antihypertensive...
Study design: An open- label, multicentre study was conducted to evaluate the antihypertensive effic...
Purposes: The purpose of this study was threefold. First, to examine how both the effectiveness of v...
Study design: An open- label, multicentre study was conducted to evaluate the antihypertensive effic...
Purpose: Blood pressure variability is associated with traditional cardiovascular risk factors, but ...
term Use Evaluation (VALUE) study compares cardiovascu-lar outcomes in 15,314 eligible patients from...
Background: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) study compares cardiovas...
BACKGROUND: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to te...
Purpose: The VALUE Trial compares cardiovascular outcomes in 15,314 eligible patients from 31 countr...
Essential hypertension is a major Public Health issue. Although the number of treated hypertensive p...
BACKGROUND: In the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial the primary out...
(VALUE) trial was designed to test whether, for the same achieved blood pressures, regimens based on...
SummaryBackgroundHypertensive patients with established cardiovascular or renal disease (ECVRD) have...
Valsartan is an orally active, selective antagonist of the angiotensin II-1 (AT1) receptor developed...
SummaryBackgroundEuropean guidelines recommend that antihypertensive management should be graded as ...
OBJECTIVE: The ambulatory blood pressure (ABP) monitoring substudy of the Valsartan Antihypertensive...
Study design: An open- label, multicentre study was conducted to evaluate the antihypertensive effic...
Purposes: The purpose of this study was threefold. First, to examine how both the effectiveness of v...
Study design: An open- label, multicentre study was conducted to evaluate the antihypertensive effic...
Purpose: Blood pressure variability is associated with traditional cardiovascular risk factors, but ...